Pharmacokinetic Considerations for Drug Dosing in Neonatal and Pediatric Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Neonatal and pediatric veterinary patients exhibit significantly altered pharmacokinetics compared to adults due to developmental changes in body composition, organ function, and enzyme expression, necessitating age-specific dosing rather than simple weight scaling.
• Reduced gastric acid secretion and slower gastric emptying in neonates impact oral drug absorption, while increased cutaneous absorption due to thinner stratum corneum and greater perfusion warrants caution with topical medications.
• Expanded total body water and reduced plasma protein binding in neonates lead to a larger volume of distribution for hydrophilic drugs and an increased free fraction of highly protein-bound drugs, respectively, elevating toxicity risk.
• Immature hepatic cytochrome P450 activity and glucuronidation pathways result in reduced drug metabolism and prolonged half-lives for hepatically cleared drugs, while low glomerular filtration rates and immature tubular secretion in neonates necessitate extended dosing intervals for renally eliminated drugs.
• Critical illness, therapeutic hypothermia, and extracorporeal circuits impose additional pharmacokinetic distortions, such as increased volume of distribution and altered clearance, requiring careful monitoring and dose adjustments beyond developmental considerations.
• Therapeutic drug monitoring, particularly for drugs with narrow therapeutic indices like aminoglycosides, is the most reliable method for optimizing dosing, with extended dosing intervals being a primary strategy to manage immature renal clearance.

Neonatal and pediatric veterinary patients present a distinct pharmacokinetic profile that diverges substantially from adult animals of the same species. Developmental changes in body composition, organ perfusion, enzyme expression, and excretory capacity alter how drugs are absorbed, distributed, metabolized, and eliminated. Dosing regimens extrapolated from adult patients by simple weight scaling frequently produce subtherapeutic or toxic exposures in young animals. This article reviews the developmental physiology that governs drug disposition in neonatal and pediatric dogs, cats, and other domestic species, and translates those principles into practical dosing decisions for the clinical setting.

The practicing veterinarian managing pediatric patients must distinguish between predictable, developmentally appropriate pharmacokinetic variation and true disease-related derangement. The evidence base for pediatric veterinary pharmacology is thinner than for human neonatology, and much of the mechanistic framework derives from human and laboratory animal research. Where species-specific data are lacking, the clinician should apply physiologic principles with caution and monitor therapeutic response and adverse effects closely. Current formulary references and label information must be consulted for specific doses, as the ranges cited in this article are illustrative of pharmacokinetic principles instead of prescriptive.

At a Glance

Developmental Physiology of Drug Absorption

Gastric acid secretion is reduced in neonates across species, raising gastric pH and altering the ionization state of weakly acidic and weakly basic drugs. A weakly acidic drug such as a nonsteroidal anti-inflammatory may exhibit reduced absorption in the relatively alkaline neonatal stomach, while weakly basic drugs may show enhanced absorption. Gastric emptying is slower in neonates, delaying time to peak concentration for orally administered drugs. Intestinal motility and surface area also mature postnatally, and biliary function, which facilitates absorption of lipophilic compounds, is immature.

Cutaneous absorption is enhanced in neonates due to thinner stratum corneum and greater skin perfusion relative to body mass. Topically applied drugs, including parasiticides and antiseptics, can produce systemic exposures several-fold higher than in adults. This route should be used with particular caution in neonatal patients, and label age restrictions for topical products should be observed. The MSD Veterinary Manual, Professional Edition provides species-specific guidance on topical drug use in young animals.

Intramuscular and subcutaneous absorption are influenced by low muscle mass, reduced regional blood flow, and the higher water content of neonatal tissues. Drugs administered by these routes may be absorbed more slowly and erratically than in adults, although the clinical significance varies by drug and species.

Volume of Distribution and Protein Binding

Total body water constitutes approximately 75% to 80% of body weight in neonates, compared with 55% to 60% in adults. Hydrophilic drugs distribute into this expanded fluid compartment, producing lower peak concentrations for a given milligram per kilogram dose. Conversely, the low body fat content of neonates reduces the distribution volume for lipophilic drugs, potentially increasing their plasma concentrations.

Plasma protein concentrations, particularly albumin and alpha-1 acid glycoprotein, are lower in neonates. Reduced protein binding increases the free, pharmacologically active fraction of highly protein-bound drugs. For a drug like a nonsteroidal anti-inflammatory that is more than 95% protein bound in adults, even a modest reduction in binding can substantially increase free drug concentration and the risk of toxicity. The clinical consequence is that total plasma concentrations may appear low while free concentrations are adequate or excessive, complicating therapeutic drug monitoring.

Hepatic Drug Metabolism

The cytochrome P450 enzyme system matures in an isoform-specific pattern that differs between species. In dogs, overall oxidative metabolic capacity is low at birth and increases over the first several weeks of life, but individual CYP isoforms mature at different rates. Glucuronidation, a phase II conjugation pathway, is particularly immature in neonates across species, which has direct consequences for drugs such as morphine and acetaminophen that rely on this pathway for elimination. Sulfation, by contrast, is relatively well developed at birth and may partially compensate for deficient glucuronidation.

Therapeutic hypothermia, used in human neonatal encephalopathy, further reduces drug metabolism through temperature-dependent enzyme inhibition. A physiology-based pharmacokinetic framework for hypothermic neonates documents reduced renal drug elimination and limited data on metabolic changes, highlighting the need for covariate-adjusted dosing in this setting physiology-based pharmacokinetic framework for therapeutic hypothermia in neonates. Veterinary neonatology does not commonly employ therapeutic hypothermia, but the principle that physiologic stressors compound developmental immaturity applies to critically ill pediatric patients generally.

Renal Excretion

Glomerular filtration rate is low at birth and increases rapidly over the first weeks of life, reaching adult values by approximately 2 to 3 months of age in dogs. Tubular secretion and reabsorption mature more slowly. Drugs eliminated primarily by renal excretion, including aminoglycosides and many beta-lactams, accumulate if dosing intervals are not extended. The clinical consequence is that once-daily aminoglycoside regimens, which are established in human neonatal sepsis, may require further interval adjustment in veterinary neonates once daily gentamicin dosing in neonatal sepsis. Renal function should be assessed before initiating renally eliminated drugs, and monitoring of serum creatinine and urine output is advised during therapy.

Extracorporeal Circuits and Critical Illness

Critically ill neonatal patients may require extracorporeal membrane oxygenation or other support modalities that alter drug disposition. The circuit itself sequesters lipophilic drugs and increases the volume of distribution, often necessitating higher initial doses. A review of anti-infective pharmacokinetics during extracorporeal membrane oxygenation, drawn largely from human neonatal studies, demonstrates larger volumes of distribution and the need for dose adjustment pharmacokinetics of anti-infective drugs during extracorporeal membrane oxygenation. Veterinary critical care units that employ such modalities should apply these principles with species-specific monitoring.

Practical Dosing Frameworks for Neonatal and Pediatric Patients

A Structured Approach to Dose Selection

The first decision is whether to dose by body weight alone or to incorporate age-based adjustment. Body weight is the default starting point, but it fails to capture the non-linear maturation of clearance pathways. A practical sequence begins with an accurate body weight, proceeds to an assessment of post-natal age and gestational age where relevant, and then applies a drug-specific adjustment factor based on the dominant elimination pathway.

For drugs cleared predominantly by the kidney, the clinician should estimate glomerular filtration rate using an age-appropriate method instead of assuming adult function per kilogram. For hepatically cleared drugs, the maturity of specific cytochrome P450 isoforms matters more than total liver mass. The prescriber must also ask whether the patient is critically ill, because hypothermia, extracorporeal circuits, and organ dysfunction each impose additional pharmacokinetic distortion on top of developmental immaturity.

Therapeutic drug monitoring is the most reliable corrective tool. When available, measure peak and trough concentrations for aminoglycosides, and adjust the interval instead of the dose when trough concentrations are elevated. For drugs without available assays, choose agents with wider therapeutic indices in neonates whenever the clinical situation permits.

Age-Related Pharmacokinetic Changes and Dosing Adjustments

The table below summarizes the principal developmental changes and their practical dosing consequences. These are general patterns, not fixed rules. The correct adjustment depends on the specific drug, the formulation, and the patient's clinical trajectory.

The most common dosing error in neonates is under-dosing the loading dose while over-dosing the maintenance dose. Because the volume of distribution for hydrophilic drugs is expanded, the loading dose often needs to be higher per kilogram than in adults. Because clearance is reduced, the maintenance interval must be extended. These two corrections move in opposite directions, and conflating them produces subtherapeutic peaks with toxic troughs.

Aminoglycoside Dosing as a Worked Example

Aminoglycosides illustrate the interaction between developmental pharmacokinetics and practical dosing strategy. The Cochrane review comparing once-daily with multiple-daily gentamicin regimens in neonates found that once-daily dosing achieved adequate sepsis clearance while offering pharmacokinetic advantages over traditional regimens once-daily gentamicin in neonatal sepsis. The earlier version of the same review reached similar conclusions, noting that pharmacokinetic studies and retrospective audits in neonatal populations favour once-daily administration neonatal gentamicin dosing interval evidence.

The clinical implication is that extending the dosing interval is the primary lever for managing developmental clearance immaturity. A term neonate in the first week of life clears gentamicin more slowly than the same infant at one month. A preterm infant clears it more slowly still. The prescriber should select an initial interval based on post-natal age and gestational age, then verify the choice with measured concentrations.

Monitoring parameters for aminoglycoside therapy include trough concentration as the principal safety marker, peak concentration where efficacy is in question, and serial serum creatinine to track renal function. A rising trough with stable dosing indicates accumulating drug and demands interval extension, not dose reduction. A low peak with a documented severe infection may justify a higher individual dose, but only after confirming that the trough remains acceptable.

Critical Illness and Extracorporeal Circuits

Critical illness superimposes non-developmental pharmacokinetic changes on the immature patient. Extracorporeal membrane oxygenation expands the volume of distribution for many drugs because the circuit adds a substantial priming volume and introduces adsorptive surfaces. A review of anti-infective pharmacokinetics during extracorporeal membrane oxygenation found that most data come from neonatal studies from the 1980s and 1990s, and these studies generally demonstrate a larger volume of distribution requiring higher initial doses anti-infective pharmacokinetics during ECMO.

Therapeutic hypothermia adds another layer of complexity. Hypothermia reduces metabolic rate and alters drug clearance, with reduced renal elimination being well documented in neonates with perinatal asphyxia undergoing cooling physiology-based pharmacokinetic framework for hypothermic neonates. The same review notes that the impact of hypothermia on hepatic drug metabolism is less well characterized, creating genuine uncertainty for drugs cleared by that route.

Erythropoietin pharmacokinetics during hypothermia illustrate the magnitude of these effects. In a phase I study of neonates undergoing hypothermia for hypoxic-ischemic encephalopathy, drug clearance at a given dose was slower than reported in uncooled preterm infants, and half-life increased with dose erythropoietin pharmacokinetics during therapeutic hypothermia. The practical lesson is that dosing regimens derived from normothermic patients cannot be assumed to apply during cooling, and that re-warming will change clearance again.

Species-Specific and Production System Considerations

The principles above apply across species, but the practical expression differs. In puppies and kittens, the same developmental trajectory of hepatic and renal maturation occurs, but the time course is compressed relative to human infants. Weaning age, body composition at birth, and the maturity of specific enzyme isoforms vary by species, so extrapolation from human neonatal pharmacology is unreliable.

In food animal neonates, withdrawal intervals are a further constraint. The FDA Center for Veterinary Medicine provides regulatory information on approved animal drugs and extralabel use, and prescribers must verify that any extralabel dosing in production animals complies with applicable rules. The WOAH terrestrial animal health standards address trade-related residue concerns that may influence drug choice in food animals.

Antimicrobial stewardship adds another layer. The AVMA antimicrobial use and stewardship resources emphasize judicious use, and this is particularly relevant in neonates where the therapeutic index is narrow and the consequences of resistance are severe. When multiple drugs are equally appropriate, the one with the widest therapeutic margin and the least propensity to select for resistance should be chosen.

Monitoring and Documentation

Monitoring frequency depends on the drug, the patient's trajectory, and the available equipment. For renally cleared drugs, serum creatinine should be measured at baseline and repeated at intervals appropriate to the drug's half-life. For hepatically cleared drugs, liver enzyme activity provides a crude but useful signal. For drugs with narrow therapeutic indices, direct concentration measurement is the standard of care where available.

Documentation should record the rationale for dose selection, including the age-based adjustments applied, the monitoring plan, and the criteria for dose modification. This record supports continuity when care is transferred between clinicians and provides the basis for retrospective review of dosing decisions. Where therapeutic drug monitoring is used, the measured concentrations, the timing of samples, and the resulting dose changes should be documented together so that the relationship between dose and exposure is traceable.

Recognized Complications and Early Detection

Therapeutic failure in neonatal patients usually presents as either subtherapeutic exposure or drug accumulation. Subtherapeutic exposure manifests as persistent clinical signs, failure to sterilize a normally responsive infection site, or breakthrough fever. Accumulation presents more insidiously: prolonged sedation, bradycardia, hypotension, or progressive azotaemia in a patient whose renal function was previously stable.

Early detection depends on structured monitoring instead of clinical instinct. For renally cleared drugs, serum creatinine should be measured at baseline and again after 48 to 72 hours of therapy, because neonatal glomerular filtration rate changes daily in the first weeks of life. For drugs with narrow therapeutic windows, therapeutic drug monitoring is indicated when available. Aminoglycoside trough concentrations remain the most practical accumulation marker, and the evidence base supporting once-daily regimens in neonates is well established in systematic reviews of randomised trials once-daily versus multiple-daily gentamicin in neonatal sepsis. When monitoring is unavailable, limit therapy duration and reassess the indication daily.

Hypothermia and extracorporeal circuits complicate interpretation of routine monitoring. Therapeutic hypothermia slows drug clearance, and the effect is not uniform across drug classes. Reduced renal elimination is well documented, while the impact on hepatic metabolism remains incompletely characterized physiology-based pharmacokinetic modeling during neonatal therapeutic hypothermia. Extracorporeal membrane oxygenation increases volume of distribution for many drugs, particularly lipophilic agents, and sequestration within the circuit can lower measured concentrations unpredictably pharmacokinetic changes during extracorporeal membrane oxygenation. In these settings, interpret a single concentration with caution and repeat sampling before adjusting doses.

Common Errors and Corrective Actions

The most frequent error is extrapolating an adult or juvenile dose by simple body weight scaling. Neonatal clearance is not proportional to weight, and this approach produces both underdosing of rapidly cleared drugs and overdosing of slowly cleared drugs. Correct by using published neonatal dosing tables from a current formulary and by recalculating the dose when the patient crosses a developmental milestone, such as renal maturation at 4 to 6 weeks of age.

A second error is assuming that oral absorption is predictable in sick neonates. Reduced gastric acid secretion, delayed gastric emptying, and reduced intestinal motility alter both the rate and extent of absorption. Clinicians should not assume that a drug known to be well absorbed in adults behaves identically in a neonatal puppy or kitten. When clinical response is inadequate, verify administration technique, consider malabsorption, and measure a peak concentration if assay support is available.

A third error is failing to adjust the dosing interval when renal function changes during therapy. A dose interval selected on day one may be inappropriate by day five. Repeat renal assessment and lengthen intervals for renally cleared drugs as azotaemia develops.

Limitations of the Evidence

The evidence base for neonatal veterinary pharmacology is thin. Most pharmacokinetic data derive from human neonatal studies, laboratory animal work, or extrapolation from older animals of the same species. Direct transfer of human neonatal principles to veterinary patients is reasonable for shared physiological processes but fails where species differences matter, such as the timing of hepatic enzyme maturation or the duration of maternal antibody transfer.

Expert opinion still differs on several points. The optimal dosing interval for aminoglycosides in premature or low-birth-weight neonates remains debated, although the available trial data favour extended intervals once-daily gentamicin regimens in neonates. Whether therapeutic hypothermia requires routine dose reduction for all hepatically cleared drugs is unresolved, and current guidance is to monitor effect instead of apply a fixed reduction. The interaction between critical illness, organ immaturity, and drug disposition is sufficiently complex that individualised dosing based on measured concentrations is preferable to formula-based dosing whenever feasible.

Referral, Consultation, and Reporting

Referral or specialist consultation is warranted when a patient fails to respond to a rationally selected and correctly administered regimen, when therapeutic drug monitoring is needed but unavailable locally, or when the clinical picture suggests an adverse drug reaction that requires investigation. Clinical pharmacologists and veterinary teaching hospitals can provide assay support and dosing advice for drugs with narrow therapeutic indices.

Laboratory involvement extends beyond routine biochemistry. Drug concentration measurement, when available, should be used to confirm suspected toxicity or subtherapeutic exposure instead of as a screening tool. For production animals, extralabel drug use in neonatal food animals carries residue implications, and practitioners should consult current regulatory guidance on withdrawal intervals and prohibited substances FDA Center for Veterinary Medicine animal drug information. Adverse drug events suspected to be related to an approved product should be reported through the relevant pharmacovigilance pathway, and antimicrobial use in food animals should follow professional stewardship principles AVMA antimicrobial stewardship guidance. International movement of treated animals may also trigger trade-related requirements, and practitioners should consult applicable animal health standards WOAH terrestrial animal health standards.

Frequently Asked Questions

How should I adjust aminoglycoside dosing when therapeutic drug monitoring is unavailable?

When laboratory access is limited, extend the dosing interval instead of reduce the dose. Once-daily regimens in neonates achieve adequate sepsis clearance with favorable pharmacokinetic profiles compared with multiple daily doses, as summarized in the Cochrane review of once-daily gentamicin in neonates. Monitor clinical response, urine output, and serial creatinine as surrogate markers. If renal function deteriorates, lengthen the interval further. Document the absence of peak and trough data explicitly in the medical record. Regional laboratory services may offer dried blood spot analysis, so inquire before abandoning therapeutic drug monitoring entirely.

What practical steps reduce dosing errors when compounding pediatric formulations?

Use commercially available pediatric concentrations whenever possible, and verify the concentration against the label before each draw. For compounded suspensions, confirm the source of the active pharmaceutical ingredient and the stability date. Weigh each patient immediately before prescribing, because body weight changes rapidly in neonates. Have a second person independently calculate the dose and the volume to administer. Record the calculation method, the formulation concentration, and the person who verified the math. The FDA Center for Veterinary Medicine publishes compounding policy and adverse event reporting pathways that apply to extralabel drug preparation.

How do I dose drugs in a neonatal patient undergoing therapeutic hypothermia?

Therapeutic hypothermia reduces drug clearance through decreased cardiac output, reduced renal perfusion, and slowed hepatic enzyme activity. The physiology-based pharmacokinetic framework for hypothermic neonates identifies reduced renal elimination as well documented, while metabolic effects remain less characterized. Start with the lower end of the age-appropriate dose range and extend intervals for renally cleared drugs. Monitor drug effect and adverse events closely, because accumulation may occur over multiple doses. Re-evaluate the dosing plan at rewarming, since clearance can change rapidly as metabolic rate and organ perfusion normalize.

What should I tell a client when their puppy or kitten needs a drug with a narrow therapeutic index?

Explain that young animals process medications differently from adults, and that the dose is calculated specifically for the patient's current weight and age. State that blood testing may be needed to confirm the drug level is in the effective range without being toxic. Describe the specific signs of toxicity to watch for, such as vomiting, lethargy, or wobbliness, and give clear instructions to call immediately if these appear. Emphasize that the dose may change as the animal grows, so follow-up visits are part of the treatment plan. The MSD Veterinary Manual provides client-level summaries that can reinforce your verbal instructions.

How does dosing differ when treating a neonatal foal compared with a puppy or kitten?

Foals are precocial and have more mature hepatic and renal function at birth than altricial puppies and kittens, but they still differ from adult horses in drug clearance. Body weight changes rapidly in all three species, so recheck weights daily during critical illness. Foals may be treated in a hospital setting with continuous rate infusion capabilities, while puppies and kittens are often discharged with owner-administered medications, which changes the reliability of the dosing schedule. Species-specific formularies should be consulted, and the WOAH terrestrial animal health standards may apply when treating food-producing juveniles.

What documentation is required when prescribing extralabel drugs to a juvenile patient?

Record the patient's age, weight, diagnosis, the drug selected, the dose calculation, and the rationale for choosing that drug over an approved alternative. Note the expected duration of therapy and the monitoring plan. For food-producing animals, document the extended withdrawal interval and inform the owner in writing. The AVMA antimicrobial stewardship resources outline principles for judicious use that apply to young patients, where resistance selection can have long-term consequences. Keep the record contemporaneous and legible, and include the client's acknowledgment that they understood the instructions.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.. 2016.
• A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.. 2020.
• One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.. 2011.
• Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.. 2009.
• Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.. 2012.
• One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.. 2006.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations
• Pharmacokinetic Drug Interactions in Veterinary Patients: Mechanisms and Clinical Relevance
• Drug Interactions with Antihypertensive Medications in Veterinary Patients
• Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients
• Pharmacokinetics in Veterinary Patients: Clinical Application of Drug Disposition

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.